Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bevacizumab.

Lee M Ellis1

  • 1University of Texas MD Anderson Cancer Center, Houston 77230-1402, USA. lellis@mdanderson.org

Nature Reviews. Drug Discovery
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Bevacizumab, an antibody targeting vascular endothelial growth factor, is approved for metastatic colorectal cancer. It is the first agent approved to target tumor angiogenesis, marking a significant advancement in cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in <i>KRAS</i>-mutated colorectal cancer.

Therapeutic advances in medical oncology·2024
Same author

Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling.

Gastroenterology·2024
Same author

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in <i>KRAS</i> -mutated colorectal cancer.

bioRxiv : the preprint server for biology·2024
Same author

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.

Molecular cancer therapeutics·2023
Same author

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.

PloS one·2023
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Metastatic colorectal cancer (mCRC) presents significant treatment challenges.
  • Tumor angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
  • Targeting tumor angiogenesis offers a novel therapeutic strategy.

Purpose of the Study:

  • To introduce Bevacizumab (Avastin) as a targeted therapy for mCRC.
  • To highlight its mechanism of action in inhibiting vascular endothelial growth factor (VEGF).
  • To note its FDA approval for first-line mCRC treatment.

Main Methods:

  • Bevacizumab is a monoclonal antibody.
  • It targets and inhibits vascular endothelial growth factor (VEGF).
  • Approved for use with 5-fluorouracil-based chemotherapy.

Related Experiment Videos

Main Results:

  • Bevacizumab represents the first approved agent targeting tumor angiogenesis.
  • Demonstrated efficacy in combination therapy for mCRC.

Conclusions:

  • Bevacizumab offers a new therapeutic approach for mCRC by targeting angiogenesis.
  • Its approval signifies a milestone in anti-angiogenic cancer therapy.